series B, venture capital funding

Remix Therapeutics Raises $70 Million in Series B Financing

Pubblicato il da CashInvoice
18
Mag
USA – Remix Therapeutics, a Cambridge, MA-based biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, raised $70M in Series B funding.

The round was led by Surveyor with participation from Foresite Capital, Atlas Venture, The Column Group, Arch Venture Partners, Alexandria Venture Investments, and Casdin Capital.

The company intends to use the funds to support development its REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

Led by Peter Smith, Ph.D., Co-Founder and Chief Executive Officer, Remix Therapeutics leverages data analytics, high-throughput screening technologies, and next generation chemistry to advance a pipeline of breakthrough therapies. The company’s innovative approach has the unique ability to precisely identify and target RNA processing steps to enhance or eliminate protein function, or to correct dysregulation in disease.Remix recently entered into a strategic collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix’s REMaster drug discovery platform.18/05/2022

CashInvoice